title: The electrocardiographic window of opportunity to treat vs. the different evolving stages of ST-elevation myocardial infarction: correlation with therapeutic approach, coronary anatomy, and outcome in the DANAMI-2 trial.
abstract: OBJECTIVE
  The aim of the study was to assess two distinct 12-lead electrocardiogram (ECG) patterns and their prognostic value with respect to reperfusion strategy.
  
  
  RESULTS
  In a DANAMI-2 substudy (n = 1522), we defined the pre-infarction syndrome (PIS) as ST-elevation accompanied by positive T waves and evolving myocardial infarction (EMI) as pathological Q waves and/or negative T wave. We used a composite of death, clinical re-infarction, or disabling stroke at median 2.7 year follow-up. A higher overall event rate was observed in the EMI group compared with the PIS group [11.4 (9.4-13.9) and 6.9 (6.0-8.0) per 100 person-years, respectively, ratio of the rate (RR) 1.6, P < 0.001]. The EMI pattern was independently predictive of adverse outcome in multivariable analysis (hazard ratio 1.52, confidence interval 1.01-2.30, P = 0.04). The PIS pattern (n = 952) was associated with lower overall event rate in patients treated with primary percutaneous coronary intervention (PCI) compared with fibrinolytic therapy (FT) [5.5 (4.4-6.9) and 8.5 (7.0-10.4) per 100 person-years, respectively, RR = 0.6, P = 0.004]. No significant difference in the outcome between treatment strategies was observed in the EMI group as a whole. However, in patients with anterior EMI without ECG signs of reperfusion, superiority of primary PCI was driven by a 51% reduction in the relative risk of composite endpoint (P = 0.008).
  
  
  CONCLUSIONS
  More detailed ECG analysis, involving also Q- and T-wave morphology, is useful for rapid identification of high-risk patients in whom every effort should be made to transfer for primary PCI, or vice versa, for identifying low-risk patients in whom FT might be an alternative option.
authors.affiliation: Department of Cardiology, Heart Center, Tampere University Hospital, Biokatu 6, Tampere, Finland. markku.eskola@pshp.fi
authors.forename: Markku J
authors.initials: MJ
authors.lastname: Eskola
authors.forename: Lene
authors.initials: L
authors.lastname: Holmvang
authors.forename: Kjell C
authors.initials: KC
authors.lastname: Nikus
authors.forename: Samuel
authors.initials: S
authors.lastname: Sclarovsky
authors.forename: Hans-Henrik
authors.initials: HH
authors.lastname: Tilsted
authors.forename: Heini
authors.initials: H
authors.lastname: Huhtala
authors.forename: Kari O
authors.initials: KO
authors.lastname: Niemelä
authors.forename: Peter
authors.initials: P
authors.lastname: Clemmensen
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods / Q000401:mortality; D004562:Electrocardiography / Q000379:methods*; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy; D015912:Thrombolytic Therapy / Q000379:methods / Q000401:mortality; D016896:Treatment Outcome